IJBPAS, September, 2026, 15(9): 4139-4149

ISSN: 2277–4998

International Journal of Biology, Pharmacy and Allied Sciences (IJBPAS)

'A Bridge Between Laboratory and Reader'

www.ijbpas.com

GAUCHER'S DISEASE AND ITS SYSTEMIC IMPACT AN INTEGRATIVE REVIEW

VASANTHA G[1*] AND MOUNIKA M[2]

1: Associate Professor, HoD, Department of Pharmacology. Vignan Institute of Pharmaceutical Technology (A), Duvvada Visakhapatnam, Andhra Pradesh, 530049, India

2: Master of Pharmacy Department of Pharmacology, Vignan Institute of Pharmaceutical Technology (A), Duvvada Visakhapatnam, Andhra Pradesh, 530049, India

***Corresponding Author: Dr. G. Vasantha: E Mail: drvasanthaniper@gmail.com**

Received 25th July 2025; Revised 16th Sept. 2025; Accepted 1st Feb. 2026; Available online 1st Sept. 2026

https://doi.org/10.31032/IJBPAS/2026/15.9.10419

ABSTRACT

Gaucher disease is a rare condition where the body can't break down certain fats properly. This can lead to tiredness, bone pain, and swelling in organs like the liver and spleen. With early diagnosis and treatment, life can be much easier for those affected and that typically manifests early in childhood and is characterized by injury to multiple organ systems and most prominently. This review discusses the analysis of genetics, new research tools for Gaucher disease, and biomarker research. Gaucher disease (GD) comes in three types, mainly based on how it affects the brain—but in real life, symptoms can vary a lot from person to person. Some have no brain issues, while others may show severe or slow-developing symptoms. Since GD is rare and often looks like other illnesses, it can take time to get the right diagnosis. A more personal, flexible approach can help manage it better and improve outcomes. This systematic review shows that glucosylsphingosine is the best biomarker for diagnosing the condition, keeping track of how it gets worse, and making decisions about treatment in kids. Lack of the enzyme glucocerebrosidase causes Gaucher's disease, which is the most prevalent lysosomal storage disorder.

Keywords: Bio marker, Glucosylsphingosine, Gaucher's disease, Glucocerebrosidase

1. INTRODUCTION:

Gaucher's disease must be kept in mind as a differential diagnosis when a child or an adult presents with an enlarged spleen[splenomegaly]and decreased blood cells[cytopenia] with no obvious cause, since these manifestations can occur in each of the three forms of Gaucher disease. Type 1 is most prevalent and usually does not impact the nervous system or brain. Types 2 and 3 however are referred to as neuronopathic forms because they do impact the nervous system. Type 2 is the most severe and develops rapidly-most children with this type sadly do not live beyond early childhood **[1] [2]**. Gaucher disease is one of a class of inherited disorders due to mutations in genes that assist lysosomes to function normally. The enzymes within the lysosomes might not function well, or the breakdown products don't get moved out properly. Therefore, there is accumulation of waste within cells and a myriad of symptoms and diseases over time in one of the LSDs, the sphingolipidoses, there is an impairment of the enzyme-degrading capacity of the metabolites that are crucial constituents of cell membranes and modulators of multiple signaling pathway.

2. HISTORY:

Nonetheless, a majority of what was known and researched about the disease was based on studies done in developed nations among European peoples. This was primarily due to the fact that type1 Gaucher's disease is significantly more prevalent among Ashkenazi jews, occurring in approximately 1 out of every 800 births. consequently, much of our initial understanding of the disease was derived from the way it presents in this population. Now, However, the medical world is becoming aware that type1 Gaucher's disease occurs in much of the rest of the world, in Asia and south America as well.

3. GENETICS:

There are associations made with each of the three forms with specific mutations. Overall, there are roughly 80 recognized GBA gene mutations categorized in three general classes.

Type 1 Gaucher condition is the most common form and is generally caused by having two clones of N370S mutation. It's frequently called the non-neuropathic type because it doesn't affect the brain or nervous system.

Type II Gaucher complaint is much more severe. It generally involves one or two clones of the L444P mutation and substantially affects babies and youthful children. Because of this, the complaint progresses snappily, and sorely, utmost children with type II pass down before they turn three times old.

Type III Gaucher complaint also involves the L444P mutation, but it tends to progress more sluggishly than type II. This slower course might be due to other defensive inheritable factors.

4. SIGNS AND SYMPTOMS:

Parkinson's disease.

excruciating joint pain, usually in the knees and hips.

Cognitive and olfactory impairment (Type 1)

Severe seizures, apnoea (Type 2), hypertonia, and intellectual disability. Myoclonus.

Enlarged spleen and liver[hepatosplenomegaly].

Liver cirrhosis is rare.

It is common for severe joint and bone pain to manifest in the hips and knees **[3]**.



Figure 1 [4]

5. PATHOPHYSIOLOGY:

Gaucher's disease (GD) is one such condition. It occurs when the enzyme glucocerebrosidase (GCase) doesn't work as it should because of changes, or mutations, in the **GBA1** gene **[5]**. Interestingly, two particular mutations — **E326K** and **T369M** — are closely linked to Parkinson's disease (PD). People who inherit these mutations in both copies of the gene (homozygous) don't actually develop Gaucher's disease **[6][7]**.

Infected cells are macrophages that play a very significant function in scavenging waste material like red and white blood cells, which possess a limited life expectancy **[8]**.

In **type I Gaucher's disease**, the brain and nervous system are usually spared, probably because the enzyme still works to some extent. This situation has prompted the need for alternate theories to explain illness symptoms **[9]**.



Figure 2 [10]

GL-1 and LysoGL-1 are broken down by the enzyme GBA2 into sphingosine and ceramide. S1P interacts with S1P receptors Because of this process, it is extremely improbable that S1P plays a role in the reduction of osteoblast function shown in In Mx1–Cre:GD1 mice, and in cell cultures exposed to GL-1 and LysoGL-1, removing the Gba2 gene makes GL-1 and LysoGL-1 build up even more surprisingly wipes out major symptoms of Gaucher's disease. In these mice, this genetic tweak completely reverses liver and spleen enlargement, restores normal blood cell counts, and fixes bone issues themselves are equally improbable candidates **[11][12]**.

5.1 GAUCHER ILLNESS RELATED TO GBA1:

GD, a prevalent lysosomal condition, is caused by biallelic mutations in the GBA1 gene and is quite common in Ashkenazi Jews. Lysosomal glucosylceramide (GlcCer) is broken down by GCase which is an enzyme that lives inside lysosomes, the cell's built-in recycling centers, where it helps break down specific types of fatty substances is encoded by GBA1. Reduced GCase activity causes its substrate to accumulate mostly in cells derived from monocytes, such as brain microglia and macrophages **[13]**.

5.2 GBA1-RELATED PARKINSON'S DISEASE:

In this disorder, two major changes occur in the nervous system. First, the dopamine-producing nerve cells in a part of the brain called the substantia nigra begin to die. Second, a protein called α-synuclein starts to build up inside nerve cells, clumping into structures known as Lewy bodies and Lewy neurites. Over time, these changes spread to specific areas of both the central and peripheral nervous systems, eventually giving rise to the well-known movement problems seen in Parkinson's disease.



Figure 3 [6]

6. DIAGNOSIS:

As was covered in earlier sections, Gaucher's disease can cause a wide range of symptoms, which can look very different from one person to the next.

coincide with several other children's illnesses, making differential diagnosis crucial **[14].**

TESTING FOR DIAGNOSIS:

Baseline enzyme activity of β-GBA.

Fresh blood leukocytes or dried blood spots can be used for this enzyme assay.

6.1 THE ASPIRATION OF BONE MARROW:

Although bone marrow aspiration is not required to confirm a diagnosis of GD, Spotting Gaucher cells can help confirm the diagnosis, and doctors may look for them even in people who haven't been diagnosed yet—especially if they have unexplained low platelet counts or an enlarged spleen **[15]**.

When diagnosing Gaucher's disease, doctors also look at other conditions that can cause similar fatty buildups in cells, like Niemann–Pick disease and pseudo-Gaucher disease **[16]**.

Sphingomyelinase deficiency causes sphingomyelin to build up in the cytoplasm of macrophages, which in turn causes Niemann-Pick disease.

6. 2 DISTINCTIVE DIAGNOSIS:

When diagnosing Gaucher's disease, doctors also think about other similar conditions that can cause similar symptoms and changes in cells.

Lewy body dementia **[17][18]** Parkinson's disease.

Lack of sphingomyelinase **[19][20]**.

7. CURRENT GAUCHER DISEASE TREATMENT:

7.1TREATMENT WITH ENZYME REPLACEMENT[ERT]:

Before enzyme replacement therapy (ERT), the only accessible treatment options were

joint replacement surgery, splenectomy to relieve severe cytopenia or pressure symptoms, and blood transfusions. Before enzyme replacement therapy (ERT) was available, people with type 1 Gaucher disease often experienced a severe and disabling progression of the illness **[21]**.

7.2 GAUCHER DISEASE TREATMENT USING SUBSTRATE REDUCTION THERAPY(SRT):

This strong starting point helped speed up the development of NB-DNJ (miglustat), which Actelion in Allschwil, Switzerland, would later market. In fact, close to a metric ton of NB-DNJ had already been produced for the HIV studies, so when the therapy idea surfaced in 1994, researchers could launch testing right away. Thanks to this head start, NB-DNJ went from concept in 1994, to clinical trials by 2000, and received regulatory approval just three years later, in 2003**[22][23]**.

8. PROGNOSIS:

With the use of currently available treatments, cytopenias, organomegalies, and bone manifestations can be drastically reduced, greatly enhancing a Gaucher's disease can lead to several complications that seriously affect a person's quality of life. In its most aggressive form, it can be irreversible and disabling, and unfortunately, it can still develop in some patients even when they are on targeted treatment can result in unfavourable outcomes.

The prognosis of patients with GD3 is affected by gradual neurological impairment when ERT is ineffective. Additionally, GD3 patients may pass away unexpectedly. Patients with type 2 GD always have a deadly result **[24]**.

9. ANALYSIS OF GENETICS:

Not every patient had their entire GBA gene sequenced. First, the samples were examined for mutations in L444P and N370S. The only mutations examined in a few cases were Some of the most common mutations in the GBA gene are N370S, L444P, D409H, G377S, N396T, the 55-base-pair deletion, and N188S They did these using techniques like long-chain PCR, nested PCR, or other PCR methods with primers designed specifically for the GBA gene. To find any new mutations, DNA sequencing was performed on the amplification products. If available, the parents' genotypes were used to determine the phase in double-heterozygous patients **[25]**.

10. EPIDEMIOLOGY:

The incidence of the disease is approximately 1/40,000 to 1/60,000 in the general population but can be as high as 1/800 in the Ashkenazi Jewish population **[4]**.

Gaucher disease is the most prevalent autosomal recessive disorder of the Ashkenazi (Eastern European) Jewish

community with a carrier rate of 6% vs. Among Ashkenazi Jews, Gaucher disease affects about 0.7% to 0.8% of the population, and carrier rates for other inherited conditions are also relatively high—around 4% for cystic fibrosis and 3.7% for Tay-Sachs disease **[26]**. The most common type of Gaucher disease is type 1.

11. THE DEVELOPMENT OF NEW RESEARCH TOOLS:

11.1 MOUSE MODELS OF GAUCHER DISEASE:

Mouse models have played a crucial role in studying Gaucher disease—helping scientists understand how the condition develops and test potential treatments. But creating a model that truly reflects the human form of the disease has been challenging. The first Gaucher mouse model was developed in 1992 by Dr. Ginns and his team at the NIH.

Even so, this model provided valuable insights particularly into the "collodion baby" skin condition seen in the most severe cases of type 2 Gaucher disease. It also revealed that differences in skin structure and chemistry could help distinguish type 2 from type 3 in human patients. Later, Dr. Proia's group at the NIH developed new models using insertion mutagenesis. These included mice with the 'RecNciI' mutation (L444P/A456P) and mice with two copies of the L444P mutation—both of which are linked to Gaucher disease. Unfortunately, these mice also died soon after birth. To create a more viable L444P model, Dr. Proia crossbred mice carrying one L444P mutation with mice carrying a single knockout of the Ugcg gene **[27][28][29][30]**. The Futerman lab refined this approach by carefully adjusting the dose and timing of CBE injections, which made it possible to produce mice that live longer and can be studied in greater detail. Mimicking neuronopathic Gaucher disease **[31][32]**.

12. LABORATORY ABNORMALITIES:

12.1DISEASE BIOMARKER:

Nowadays, some of the most important biomarkers applied for research and tracking of Gaucher disease are chitotriosidase, CCL18, glucosylsphingosine, and ferritin. Most notably, chitotriosidase is produced abundantly by Gaucher cells and has been utilized since 1994 as a consistent marker to follow the course of the disease **[33]**. A newer biomarker, glucosylsphingosine, has been found to be more sensitive and specific than older markers like chitotriosidase and CCL18. Early studies suggest it's highly effective for monitoring Gaucher disease, although it hasn't yet been widely tested. For now, experts recommend measuring this biomarker as often as the other standard ones **[34][35]**.

In Gaucher disease, the three main biomarkers—chitotriosidase, CCL18, and glucosylsphingosine are closely connected. Their levels typically increase or decrease in

tandem, showing similar trends and strong correlations with each other **[36]**.

12.2 OTHER BIOLOGICAL TESTS:

In Gaucher disease, the usual liver function tests—free and conjugated bilirubin levels, transaminases, alkaline phosphatase, and gamma-GT—are in the normal range, but they're still worthwhile. There may be some indication in some patients by cholestasis (higher alkaline phosphatase, bilirubin, and gamma-GT), and less commonly by cytolysis (with elevated transaminases) **[37]**. C-reactive protein (CRP) can increase with bone crises (bone infarctions) or with some infections, including cholecystitis, more frequently in patients with Gaucher disease. It is also worth doing to check serum calcium (and occasionally serum phosphorus) levels and vitamin D status. Vitamin D deficiency appears to be more common in Gaucher patients than in the general population, and supplementation is recommended strongly if 25(OH)D levels fall below 75 nmol/L.

13. FUTURE PERSPECTIVES OF GAUCHER DISEASE: **[38]**

The arrival of enzyme replacement therapy (ERT) was a major milesto ne in treating Gaucher disease, significantly improving patient outcomes and osteonecrosis of bone, severe pulmonary infiltration, or cirrhosis changes of the liver have occurred, then it will bring all the parameters of disease back to normal in most patients and may lead to a nearly normal childhood Evaluation of individualized biomarkers, such as lyso-Gb1, might be helpful with diagnosis and phenotypic prediction and assessment of disease course and treatment response. For the neuronopathic variants—those involving the brain and nervous system—scientists are currently exploring a range of postnatal therapy alternatives.

CONCLUSION:

Although Gaucher disease is the most common lysosomal storage disorder, it is still considered a rare condition. In most cases, it develops slowly and subtly, which is why diagnosis is often delayed. Doctors should keep Gaucher disease in mind when assessing patients with an enlarged spleen (splenomegaly) and/or low platelet counts (thrombocytopenia), as recognizing it early can help avoid unnecessary and potentially harmful splenectomies. In Egypt, Gaucher disease is not unusual, partly due to the high rate of consanguinity (marriage between relatives). However, its exact prevalence remains unknown because there is no national Gaucher registry. This study of Gaucher disease has offered valuable insights and practical approaches that could also be applied to the study of other single-gene disorders and may even help in understanding more complex diseases.

REFERENCES:

[1] Elstein D, Abrahamov A, Hadas-Halpern I, Zimran A, Gaucher's

disease, Lancet, 358(9284), 2001, 324–327.

[2] Stirnemann J., *et al*., A review of Gaucher disease pathophysiology, clinical presentation and treatments, Int. J. Mol. Sci., 18(2), 2017, 20441.

[3] Kishnani P.S., *et al*., Screening, patient identification, evaluation, and treatment in patients with Gaucher disease: Results from a Delphi consensus, Mol. Genet. Metab., 135(2), 2022, 154–162.

[4] Grabowski G.A., Phenotype, diagnosis, and treatment of Gaucher's disease, Lancet, 372(9645), 2008, 1263–1271.

[5] The Lancet

[6] Weinreb N.J., *et al*., Life expectancy in Gaucher disease type 1, Am. J. Hematol., 83(12), 2008, 896–900.

[7] Dahl N, Lagerström M, Erikson A, Pettersson U, Gaucher disease: type III (Norrbottnian type) is caused by a single mutation in exon 10 of the glucocerebrosidase gene, American Journal of Human Genetics, 47(2), 1990, 275–278.

[8] McNeill A, Duran R, Hughes DA, Mehta A, Schapira AHV, A clinical and family history study of Parkinson's disease in heterozygous glucocerebrosidase mutation carriers, Journal of Neurology, Neurosurgery, and Psychiatry, 83(8), 2012, 853–854.

[9] Rajkumar V, Dumpa V, Lysosomal Storage Disease, Treasurland (FL), 2025.

[10] Feng S, *et al*., A review on Gaucher disease: therapeutic potential of β-glucocerebrosidase targeted mRNA/saRNA approach, International Journal of Biological Sciences, 20(6), 2024, 2111–2129.

[11] Horowitz M, Braunstein H, Zimran A, Revel-Vilk S, Goker-Alpan O, Lysosomal functions and dysfunctions: Molecular and cellular mechanisms underlying Gaucher disease and its association with Parkinson disease, Advanced Drug Delivery Reviews, 187, 2022, 114402.

[12] Mehta A, Epidemiology and natural history of Gaucher's disease, European Journal of Internal Medicine, 17(Suppl), 2006, S2.

[13] Kałużna I, Trzeciak K, Ziemnicka K, Machaczka M, Ruchała M, Endocrine and metabolic disorders in patients with Gaucher disease type 1: a review, Orphanet Journal of Rare Diseases, 14(1), 2019, 275.

[14] Mistry K, *et al*., Glucocerebrosidase 2 gene deletion rescues type 1 Gaucher disease,

Proceedings of the National Academy of Sciences USA, 111(13), 2014, 4934–4939.

[15] Ogretmen B, Hannun YA, Biologically active sphingolipids in cancer pathogenesis and treatment, Nature Reviews Cancer, 4(8), 2004, 604–616.

[16] Weiss A, Gonzalez A, Lopez L, Pedeutour C, Groden E, Sidransky E, The clinical management of Type 2 Gaucher disease, Molecular Genetics and Metabolism, 114(2), 2015, 110–122.

[17] El-Beshlawy A, Diagnosis and management of patients with Gaucher disease: an Egyptian expert opinion, Egyptian Journal of Medical Human Genetics, 25(1), 2024, 5.

[18] Yoshida *et al*., Prenatal diagnosis of Gaucher disease using next-generation sequencing, Pediatrics International, 58(9), 2016, 946–949.

[19] Rosenberg N, Giladi N, Gaucher's Disease, Encyclopedia of Movement Disorders, Three-Volume Set, VI-531–534, 2010.

[20] Di Rocco M, Screening for lysosomal diseases in a selected pediatric population: the case of Gaucher disease and acid sphingomyelinase deficiency, Orphanet Journal of Rare Diseases, 18(1), 2023, 197.

[21] Bossù G, Pedretti L, Bertolini L, Esposito S, Pediatric Gaucher Disease Presenting with Massive Splenomegaly and Hepatic Gaucheroma, Children (Basel), 10(5), 2023, 5869.

[22] Oliva E, Importance to include differential diagnostics for acid sphingomyelinase deficiency (ASMD) in patients suspected to have Gaucher disease, Molecular Genetics and Metabolism, 139(1), 2023, 107563.

[23] Garça S, Correia A, Goulart A, Avila P, Gaucher Disease: One of the Few Causes of Massive Splenomegaly, European Journal of Case Reports in Internal Medicine, 9(12), 2022, 3705.

[24] Mistry K, Lopez R, Schiffmann R, Barton NW, Weinreb NJ, Sidransky E, Gaucher disease: Progress and ongoing challenges, Molecular Genetics and Metabolism, 120(1–2), 2017, 8–21.

[25] Platt FM, Neises GB, Karlsson BG, Dwek RA, Butters TD, N-butyldeoxynojirimycin inhibits glycolipid biosynthesis but does not affect N-linked oligosaccharide processing, Journal of Biological

Chemistry, 269(43), 1994, 27108–27114.

[26] Radin NS, Treatment of Gaucher disease with an enzyme inhibitor, Glycoconjugate Journal, 13(2), 1996, 153–157.

[27] Abdelwahab M, Blankenship A, Schiffmann R, Long-term follow-up and sudden unexpected death in Gaucher disease type 3 in Egypt, Neurology: Genetics, 2(2), 2016, e55.

[28] Giraldo E, Mapping the genetic and clinical characteristics of Gaucher disease in the Iberian Peninsula, Orphanet J Rare Dis, 7, 2012, 17.

[29] Stirnemann J, A review of Gaucher disease pathophysiology, clinical presentation and treatments, Int J Mol Sci, 18(2), 2017, 1-30.

[30] Wang F, Zhang L, Lu C, Kong W, Global epidemiology of Gaucher Disease: an updated systematic review and meta-analysis, J Pediatr Hematol Oncol, 45(4), 2023, 181-188.

[31] Tybulewicz VL, Animal model of Gaucher's disease from targeted disruption of the mouse glucocerebrosidase gene, Nature, 357(6377), 1992, 407-410.

[32] Holleran WM, Consequences of beta-glucocerebrosidase deficiency in epidermis. Ultrastructure and permeability barrier alterations in Gaucher disease, J Clin Invest, 93(4), 1994, 1756-1764.

[33] Sidransky E, Epidermal abnormalities may distinguish type 2 from type 1 and type 3 of Gaucher disease, Pediatr Res, 39(1), 1996, 134-141.

[34] Liu Y, Mice with type 2 and 3 Gaucher disease point mutations generated by a single insertion mutagenesis procedure, Proc Natl Acad Sci U S A, 95(5), 1998, 2503-2508.

[35] Kanfer JN, Stephens MC, Singh H, Legler G, The Gaucher mouse, Prog Clin Biol Res, 95, 1982, 627-644.

[36] Klein AD, Identification of modifier genes in a mouse model of Gaucher disease, Cell Rep, 16(10), 2016, 2546-2553.

[37] Hollak CE, van Weely S, van Oers MH, Aerts JM, Marked elevation of plasma chitotriosidase activity: a novel hallmark of Gaucher disease, J Clin Invest, 93(3), 1994, 1288-1292.

[38] Bargagli E, Human chitotriosidase: a sensitive biomarker of sarcoidosis, J Clin Immunol, 33(1), 2013, 264-270.